SureTrader SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Medical - Drugs >

Cellceutix Corporation (CTIX)

Add CTIX Price Alert      Hide Sticky   Hide Intro
Moderator: NotAsBigKahuna, BooDog, sox040713, Astavakra, TheHound, Matagordaville
Search This Board: 
Last Post: 2/21/2017 10:56:59 PM - Followers: 707 - Board type: Free - Posts Today: 137

Cellceutix Corporation (CTIX)
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  [email protected]
About Cellceutix: 

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin concluded a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is now preparing its FDA application for a Phase 2 ovarian cancer study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol completed a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Brilacidin is also being evaluated in a Phase 2 Proof-of-Concept trial as a novel treatment for Ulcerative Proctitis. Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at 


Ongoing Human Trials:
Product Pipeline:


FDA Designations:

Upcoming Milestones:

Recent News and Press Releases:

Seeking Alpha focus articles on CTIX:

A randomized, double-blind study comparing single-dose and short-course brilacidin to daptomycin in the treatment of acute bacterial skin & skin structure infections (ABSSSI)

Synthetic novel host defense protein mimetics for the treatment of Gram-negative bacterial infections

SEC Filings (CIK:0001355250):

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
[email protected]

Share Structure:  See SEC filing link above for current share structure

Cellceutix IP - Patent Filings:



Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
External Links: USPTO, USPTO Assignment, Espacenet

Investor Relations:  [email protected]

Following is a WEEKLY chart:


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
CTIX News: Current Report Filing (8-k) 02/16/2017 07:01:38 AM
CTIX News: Quarterly Report (10-q) 02/09/2017 04:04:17 PM
CTIX News: Current Report Filing (8-k) 02/09/2017 09:39:24 AM
CTIX News: Amended Statement of Ownership (sc 13g/a) 01/04/2017 03:58:28 PM
CTIX News: Current Report Filing (8-k) 11/15/2016 06:25:29 AM
#172374  Sticky Note PIPELINE STAGES, FDA DESIGNATIONS, UPDATE BooDog 02/17/17 08:05:49 AM
#172192  Sticky Note $CTIX - Cellceutix Reports on Q2 Fiscal 2017, KarinCA 02/16/17 07:39:33 AM
#172129  Sticky Note It seems like Dr Bertolino made reference to KarinCA 02/15/17 03:24:47 PM
#169697  Sticky Note Absolute proof that AF's intent was and is georgejjl 01/25/17 08:29:12 PM
#165552  Sticky Note B-UP Due Diligence sox040713 12/09/16 12:17:52 PM
#165491  Sticky Note New Oral Psoriasis Drug Tops Cellceutix Catalysts $CTIX http://www.seekingalpha. Matagordaville 12/08/16 04:55:12 PM
#172872   $25 million to $50 million upfront is peanuts djs7 02/21/17 10:56:59 PM
#172871   Well said... "Hey dunn. How come you don't want thefamilyman 02/21/17 10:56:10 PM
#172870   Yes he does... thefamilyman 02/21/17 10:55:07 PM
#172869   Hey dunn. How come you don't want to Barron4664 02/21/17 10:46:58 PM
#172868   SHORT SQUEEZE COMING SOON!!! georgejjl 02/21/17 10:36:51 PM
#172867   FINRA short sales of CTIX Goodbuddy4863 02/21/17 10:32:25 PM
#172866   Monmol. What is so bad about CTIX? DaubersUP 02/21/17 10:27:25 PM
#172863   Show me the $1.66 AH trades G tombrady12nh 02/21/17 10:14:13 PM
#172862   “To date, the trial has exceeded our expectations georgejjl 02/21/17 10:10:39 PM
#172861   I suggest you to read the latest 10-Q sox040713 02/21/17 09:17:47 PM
#172854   No trades for Ctix after hours! snayeman 02/21/17 08:34:34 PM
#172853   We agree again george! runninggirl2017 02/21/17 08:29:35 PM
#172851   I don't even know where to begin. F1ash 02/21/17 08:27:38 PM
#172849   Where in the contract does it say Aspire septmike09 02/21/17 08:07:32 PM
#172848   I am not sure you understand what a septmike09 02/21/17 08:02:50 PM
#172846   The problem would be the ability to raise Rdunn88 02/21/17 08:02:34 PM
#172845   They only have 2 million in debt. septmike09 02/21/17 07:57:59 PM
#172844   That's why Aspire doesn't hold shares long-term, too Rdunn88 02/21/17 07:56:30 PM
#172843   If CTIX defaults, I'm not sure Leo can Rdunn88 02/21/17 07:52:10 PM
#172841   What about the after hours trading, show us please snayeman 02/21/17 07:47:22 PM
#172840   I expect it TI be the same as tombrady12nh 02/21/17 07:45:56 PM
#172839   Expect the CTIX market capitalization to more than georgejjl 02/21/17 07:43:43 PM
#172838   George, where you seeing that? How's about a snayeman 02/21/17 07:38:24 PM
#172834   Nothing shows up on Nasdaq website. What site septmike09 02/21/17 07:30:26 PM
#172833   Sox, expansion was/is part-of-the-problem. Trying to finance one-drug Rdunn88 02/21/17 07:27:58 PM
#172832   Longs - Please keep this in mind. DaubersUP 02/21/17 07:27:27 PM
#172831   If your prediction materializes, this will be a zandant 02/21/17 07:26:27 PM
#172830   What do you mean bails them out? CTIX septmike09 02/21/17 07:25:11 PM
#172829   Do not ... Fear, uncertainty and doubt (often georgejjl 02/21/17 07:23:11 PM
#172828   If I'm Pfizer, I see 3 million in Rdunn88 02/21/17 07:12:47 PM
#172827   Hope all the way to 15 bucks JUST 10-11-12 02/21/17 07:11:41 PM
#172826   According to Schwab, there is no trade at Blues44 02/21/17 07:11:16 PM
#172825   Has anyone seen after hour trading at $1.66 today? georgejjl 02/21/17 07:05:23 PM
#172824   The true story regarding ctix is somewhere in runninggirl2017 02/21/17 06:17:02 PM
#172821   Yes. The current share price is hard to BioTechMaven 02/21/17 05:55:05 PM
#172820   Besides B-ABSSSI, did PolyMedix have four other Phase sox040713 02/21/17 05:45:20 PM
#172819   which is why Leo ain't listening to all steelyeye 02/21/17 05:43:47 PM
#172818   Amazing the kind of crap that gets spewed Waverunner1 02/21/17 05:28:57 PM
#172817   This stock is winding up so tight that eventhelosers 02/21/17 05:28:21 PM
#172816   Very parallel to Poly B-ABSSI was sureshot for Poly Amatuer17 02/21/17 05:27:21 PM
#172815   But I agree with all else you stated. joseytheoutlawwales 02/21/17 04:49:24 PM
#172814   >>"At this point, put a for-sale sign up" Not joseytheoutlawwales 02/21/17 04:49:06 PM
#172813   Put a for-sale sign up Leo and move Rdunn88 02/21/17 04:48:33 PM
#172812   Leo never addressed the finances after the first Rdunn88 02/21/17 04:44:06 PM
#172811   They shorts have already cashed in for years here Giovanni 02/21/17 04:36:48 PM
#172810   The explanation is very simple- CTIX has yet joseytheoutlawwales 02/21/17 04:36:28 PM
#172809   LOL That is great. Giovanni 02/21/17 04:34:46 PM
#172808   I think the problem is the market is septmike09 02/21/17 04:25:08 PM
#172807   Sell the news only applies when people are septmike09 02/21/17 04:20:44 PM
#172806   Sell on rumor, sell on news...... green is good 02/21/17 04:11:09 PM